Status:
ACTIVE_NOT_RECRUITING
Electrical Muscle Stimulation with 1064 Nm Diode Laser and RF/PEMF for Non-invasive Body Contouring and Fat Reduction.
Lead Sponsor:
Venus Concept
Conditions:
Fat Reduction
Muscle Tone Increased
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
Multi-center, three-arm, randomized, evaluator-blinded study of electrical muscle stimulation (EMS) and/or 1064 nm diode laser, pulsed electromagnetic field (PEMF) and vacuum assisted radio frequency ...
Detailed Description
The study will enroll up to 60 male and female subjects, ≥ 18 years of age, requesting non-invasive electrical muscle stimulation (EMS) and/or lipolysis of the abdomen and flanks. Subjects will be ran...
Eligibility Criteria
Inclusion
- Male and female subjects \> 18 years of age and ≤65 years of age.
- Subject agrees to refrain from any new abdominal training exercises during the course of the study.
- BMI ≤ 30 kg/m2 as determined at screening.
- Subject has read and signed a written informed consent form.
Exclusion
- Pregnant in the last 3 months, intending to become pregnant, postpartum or nursing in the last 6 months, including presence of post-partum diastasis.
- Any previous liposuction/lipo-sculpture or any type of surgical procedure in the treatment area in the past 12 months.
- History of immunosuppression/immune deficiency disorders (including AIDS and HIV infection) or use of immunosuppressive medications last 6 months prior to and during the course of the study.
- History of hyperlipidemia, diabetes mellitus, hepatitis, blood coagulopathy or excessive bleeding.
- Use of antiplatelet medications (81 mg acetylsalicylic acid daily permitted), anticoagulants, thrombolytics or anti-inflammatory medications within 2 weeks of treatment or a history of bleeding disorders.
- History of skin cancer or any other cancer in the areas to be treated, including presence of malignant or pre-malignant pigmented lesions.
- Having a permanent implant in the treatment area such as metal plates or an injected chemical substance such as silicone or parenteral gold therapy (gold sodium thiomalate), or drug delivery system that would prevent treatment at the treatment site.
- Use of medications, herbs, food supplements, and vitamins known to induce photosensitivity to light exposure at the wavelength used or history of photosensitivity disorder.
- Suffering from significant skin conditions in the treatment area or inflammatory skin conditions including but not limited to open lacerations, abrasions, herpes sores, cold sores, active infections.
- Tattoos in the treatment area
- Numbness, tingling or other altered sensation in the treatment area.
- Known sensitivity or allergy to isopropyl alcohol and propylene glycol, hydrogel or latex or any substance used during treatments by the clinic (if applicable).
- Unable or unwilling to comply with the study requirements.
- Enrolled in a clinical study of any other investigational drug or device.
- Any other condition or laboratory value that would, in the professional opinion of the Investigator, potentially affect the subject's response or the integrity of the data or would pose an unacceptable risk to the subject.
Key Trial Info
Start Date :
November 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 30 2025
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT05256771
Start Date
November 1 2021
End Date
September 30 2025
Last Update
March 28 2025
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Scripps Clinical Research - General Medicine
San Diego, California, United States, 92121
2
Schweiger Dermatology Group
Hackensack, New Jersey, United States, 07601
3
Tennessee Clinical Research Center
Nashville, Tennessee, United States, 37215